“Progress in HIV-1 Vaccine Development”, in 2nd National Conference on Human Retroviruses and Related Infections, Washington DC, 1995.,
“Analysis of Intercurrent Human Immunodeficiency Virus Type 1 Infections in Phase I and II Trials of Candidate AIDS Vaccines”, J Infec Dis, vol. 177, pp. 310-319, 1998.,
“Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type1 envelope with a combination vaccine regimen”, J Infec Dis, vol. 177, pp. 301-9, 1998.,
“HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine”, AIDS Res HumRetroviruses, vol. 15, pp. 115-32, 1999.,
“Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults”, J Infec Dis, vol. 177, pp. 1230-46, 1998.,
“Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus Type 1”, AIDS Res HumRetroviruses, vol. 16, pp. 2019-35, 2000.,
“A Phase II Study of Two HIV-1 Envelope Vaccines Comparing their Immunogenicity in Populations at Risk for Acquiring HIV-1 Infection”, AIDS Res HumRetroviruses, vol. 16, pp. 907-19, 2000.,
“Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers”, J Infec Dis, vol. 183, pp. 1343-52, 2001.